GlaxoSmithKline PLC to Discuss Pivotal DREAMM-2 Data on Belantamab Mafodotin (GSK'916) Call Transcript
Good day, everyone, and welcome to the DREAMM-2 call hosted by Sarah Elton-Farr. My name is Steve and I'm your event manager. (Operator Instructions). I'd like to advise all parties this conference is being recorded for replay purposes.
And now I'd like to hand over to Sarah.
Thank you. Good afternoon. Thank you for joining us here today on our call to discuss the data from the DREAMM-2 study, which was published yesterday in the Lancet Oncology. Our speakers today are Dr. Hal Barron, Chief Scientific Officer and President of R&D; Dr. Peter Voorhees, member of the Plasma Cell Disorders division from the Levine Cancer Institute; Dr. Axel Hoos, Head of Oncology R&D; and Luke Miels, President of Global Pharmaceuticals. We also have Christine Roth, Global Oncology Therapy Area Head; and Ira Gupta, Medicine Development Lead for belantamab, on the line for Q&A.
Before we begin, I'll need to refer you to our cautionary statements on slide 2.
And with that, I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |